Ben Liu

CEO, Formation Bio · Person

Mentions

Episodes

Claims

Ben Liu - CEO, Formation Bio. Tracked across 34 mentions in podcasts and expert conversations analyzed by Sonic.

What Ben Liu has said

Ben Liu predicts that the price of acquiring discovered drug assets will decrease as AI makes drug discovery more accessible and commoditized.

bearish·Ben Liu

Formation Bio's initial seed funding was $2.25 million, and its Series A round was $15 million.

neutral·Ben Liu

Ben Liu predicts that 'healthspan drugs,' which aim to help people live longer and healthier lives, will be the next major impactful drug class after GLP-1s.

bullish·Ben Liu

Ben Liu predicts that the price of acquiring discovered drug assets will decrease as AI makes drug discovery more accessible and commoditized.

SpeculativeBen LiuJul 13

Formation Bio's initial seed funding was $2.25 million, and its Series A round was $15 million.

Expert perspectiveBen LiuJul 13

Ben Liu predicts that 'healthspan drugs,' which aim to help people live longer and healthier lives, will be the next major impactful drug class after GLP-1s.

SpeculativeBen LiuJul 13

Formation Bio is structured using a 'hub and spoke' model, which allows it to sell individual drug assets without selling the entire company.

Expert perspectiveBen LiuJul 13

Formation Bio has licensed a fibroblast growth factor 18 (FGF18) drug program from Merck KGA.

Expert perspectiveBen LiuJul 13

Formation Bio's business model is to acquire already-discovered drugs rather than performing its own discovery.

Expert perspectiveBen LiuJul 13

Formation Bio uses genetic databases, including FinGen, All of Us, and UK Biobank, to systematically evaluate all potential disease indications for a given drug target.

Expert perspectiveBen LiuJul 13

Ben Liu's 'Uneven Frontiers' framework posits that AI will impact life sciences in a specific order: first drug discovery, then toxicology, and finally clinical efficacy.

Expert perspectiveBen LiuJul 13

Formation Bio has developed an AI model that uses MRI images to predict a person's likelihood of needing a knee replacement within 5 to 10 years.

Expert perspectiveBen LiuJul 13

Formation Bio has acquired a brain-penetrant TIK2 inhibitor and is using its AI platform to find novel disease indications for it.

Expert perspectiveBen LiuJul 13

There are currently 250 GLP-1 drugs in development.

Expert perspectiveBen LiuJul 13

The number of drugs approved by regulators has remained constant at approximately 50 per year over the last decade.

Expert perspectiveBen LiuJul 13

A common valuation heuristic for a biotech company after a successful Phase 2 trial is one times the drug's projected peak sales.

Expert perspectiveBen LiuJul 13

A company with a successful Phase 3 drug could be acquired for 2 to 3 times the drug's peak sales, equating to $6 to $9 billion.

Expert perspectiveBen LiuJul 13

A biotech company with a successful Phase 2 drug may receive acquisition offers of around $3 billion.

Expert perspectiveBen LiuJul 13

Under the Aditum Bio partnership, Formation Bio received minority equity in each new company formed but did not receive management fees or carry.

Expert perspectiveBen LiuJul 13

On average, only 30% of Phase 2 clinical trials are successful.

Expert perspectiveBen LiuJul 13

Phase 3 clinical trials have an average success rate of 60%, with a 40% chance of failure.

Expert perspectiveBen LiuJul 13

Formation Bio utilizes an internal AI tool named Atlas to identify and analyze potential drug acquisition targets.

Expert perspectiveBen LiuJul 13

Between 2010 and 2017, the consensus forecast for peak annual sales in the entire obesity drug market was only $1 billion to $3 billion.

Expert perspectiveBen LiuJul 13

Create a free account to see Ben Liu's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail